- Benchmark ASINB0DXF4M7L1
- MarketplaceUS
- Category ID6939041011
- Analyzed Products
- Keywordlymphatic drainage drops, lymph support drops, herbal detox drops
- Price Range-
- Minimum Net Profit Margin10.00%
- MOQ100
- Est. Purchasing CostNo price data
- Data Date2026-07-28
- Your Budget (for new listing) (CNY)¥500,000.00
Report summary from Keble AI Agent: Listing
结论很明确：这个市场不适合进入，尤其不适合小品牌；对大品牌也不是好赛道，除非你愿意为差异化和渠道投入更高预算。 当前数据没有看到新品牌跑通的证据，反而是老品牌在吃存量，整体更像低利润、强资源型竞争市场。
Recommended Products Features Direction
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
New Brands
VS
Old Brands
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
Old Brands
#Budget Requirement
Listing不建议进入这个市场。 这不是一个适合小品牌切入的赛道：可见的新品盈利率为0%，市场整体可盈利产品占比只有60%，但真正能代表新进入者的“新释放”产品没有任何盈利样本，说明新品牌几乎没有稳定胜率；同时，能赚钱的样本主要来自老品牌/既有品牌，属于资源型玩家的地盘。
Early sourcing + logistics + marketing budget (USD)N/AExplains the budgetWith all these investments, who has profitable new releases
How many new listings are released by old brands?100.00%New listing success rate (old brands):0.00%Alternatives- 同类草本滴剂中的更低价基础配方（如单一草本提取滴剂，而不是多草本“淋巴排毒”复方）
- 草本胶囊/片剂的基础配方（通常每次剂量更便宜，且在亚马逊上更容易买到）
- 单方草本茶包或冲泡粉（如蒲公英茶、荨麻茶等），作为更便宜的日常“轻排水”替代
- 电解质补水饮料粉/口服补液粉，作为更直接、便宜的“水肿感管理”替代
- 非口服的淋巴按摩/滚轮/刷痧工具，作为一次购买、无需长期补充剂的替代方案
- 基础维生素/矿物质补充剂（如镁）用于更广泛的日常身体支持，通常价格更低、认知更强
Alternative solutions may pose a risk to your investment in certain markets.
#Brands Investment Analysis
Listing不建议进入，这个市场对新卖家不友好，已经明显偏向存量竞争。 目前样本里可识别的盈利产品占60%，但新上架产品的盈利率是0%，这说明新增切入点几乎没跑通；同时近12个月里只有1个新产品样本且直接亏损，新增品牌没有任何成功案例，市场更像是老品牌守盘而不是给新玩家留空间。
Old brand with the most profitable new productsDetoxenNATURE
Recent Monthly Revenue (USD):$14,064.00(800pcs/month)B0DXF4M7L1 (4.5/5 (166 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitable#Differentiations
Unique productsCommon productsDifferentiation:- 1盎司滴管液体，和其他草本滴剂相比更便于日常服用。
- |
- 有机草本配方，主打淋巴支持+免疫支持，购买动机更明确。
- |
- 黑蓝绿色包装辨识度较高，图片在同类中更容易被点击。
B0CRRCSXVM (4.1/5 (470 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableSales & BSR
Differentiation:- 7合1草本复配，卖点组合更丰富，和单一配方差异更大。
- |
- 绿色纸盒+琥珀滴管瓶，草本感强，视觉上更像成熟保健品。
- |
- 兼顾淋巴引流、排毒和免疫支持，功能覆盖面广，吸引力更强。
B0DXF4M7L1 (4.5/5 (166 Reviews))Brand is an old entry in this marketOld ReleaseSufficient Sales to Meet MOQOld ReleaseThis listing is deemed profitableSales & BSR
#Net Profit Margins: All vs New
Listing这个市场不值得进入，结论很明确：你不该进。 现在看到的是典型的低利润竞争环境，且新品里没有形成可复制的健康利润带；对小商家来说，能成功的案例几乎没有，对大品牌来说也只是“有机会但要重投入”，不是好市场。
Profitability difficultyUnknown - Insufficient New ReleasesAll products distribution on different profit levels
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%otherNew products distribution on different profit levels
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
x < -10.0%-10.0% <= x < 0.0%0.0% <= x < 10.0%10.0% <= x < 20.0%20.0% <= x < 30.0%30.0% <= x < 40.0%x >= 40.0%other#Top Products by Net Profit Margin
Top 20 Profitable Products
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
B0DXF4M7L1DetoxenNATURE2025-02-17Yes$17.58800pcs$14064.026.86%$3777.6B0CRRCSXVMDR. BO2024-06-07Yes$15.95200pcs$3190.026.65%$850.14
B0CJRN84BSNurbetoxa2023-10-07Yes$17.6850pcs$884.029.77%$263.17Top 20 Non-Profitable New Products
New products with negative profitability ranked by lowest profit value. Only includes newly released products classified as non-profitable.
B0FRXLD2XGNurbetoxa2025-09-20No$--pcs$--%$-#New Product Success Rates
Listing这个市场不适合进入，而且对新品牌和小商家都不是好机会：新上架产品盈利率为0%，老品牌的新产品也同样是0%，说明新切入几乎没有成功空间，市场已经被成熟玩家牢牢压住。更重要的是，现有可见样本里真正赚钱的产品几乎都来自老品牌，且打法高度同质化，属于典型的高门槛、低容错市场。
New products success rate.
What is the ratio of profitable products
Profitable (Unidentifiable released date)Profitable (Old product)Profitable (New product)Profitable (New product on old listing)New products but non profitableNo data availableNonprofitable new products divide by brands
What is the ratio of different brands owning all nonprofitable new products
Nurbetoxa#Success Rate by Entry Time
Listing这个市场不值得进入，结论很明确：新品牌几乎没有成功窗口，已经是高风险的价格战市场。 现有数据里，新发布产品的可盈利率是0%，而整体可盈利产品占比虽有60%，但真正的新发布只看到1个样本、且它是失败的；这说明机会并不在“新切入”，而在老品牌继续吃存量。
How many products released each year
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
How many products released each month
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
#Net Profit Margins by Entry Time
Different profit ratios of products released in year
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2022 0 0 0 0 0 0 0 0 2023 0 0 0 0 0 0 0 0 2024 0 0 0 0 0 0 0 0 2025 0 0 0 0 0 0 0 1 2026 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiableDifferent profit ratios of products released in month
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
Time/Profit% x < -10.0% -10.0% <= x < 0.0% 0.0% <= x < 10.0% 10.0% <= x < 20.0% 20.0% <= x < 30.0% 30.0% <= x < 40.0% x >= 40.0% other 2025/7 0 0 0 0 0 0 0 0 2025/8 0 0 0 0 0 0 0 0 2025/9 0 0 0 0 0 0 0 1 2025/10 0 0 0 0 0 0 0 0 2025/11 0 0 0 0 0 0 0 0 2025/12 0 0 0 0 0 0 0 0 2026/1 0 0 0 0 0 0 0 0 2026/2 0 0 0 0 0 0 0 0 2026/3 0 0 0 0 0 0 0 0 2026/4 0 0 0 0 0 0 0 0 2026/5 0 0 0 0 0 0 0 0 2026/6 0 0 0 0 0 0 0 0 ≥ 10% Profitable< 10% UnprofitableUnidentifiable#Case Study
Success CasesNurbetoxaB0CJRN84BS (4.3/5 (249 Reviews))Nurbetoxa Cleavers Lymphatic Drainage Drops for Lymph System Support - 2oz
This listing is deemed profitablePrice (USD)$17.68Released TypeOld Release (2023-10-07)Brand is an old entry in this marketSize and Weight12.0 x 4.2 x 4.0 cm, 1.00gProfitable Factors
Based on old ASINDistinct functions and featuresKey Buying Motive
采用“清香草本+淋巴支持+免疫支持”的复合配方，并强调液体滴剂形态，适合不想吞咽胶囊的用户。Target Customers
更偏向需要淋巴排液、按摩搭配使用、以及偏好草本液体补充剂的人群。Early Investment
Investment
Monthly Revenue (Recent) (USD)$884.0050 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight28.22% / 29.77%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight27.29% / 28.84%Peak / Non PeakSales & BSR Performance
Lymphatic Drainage Supplements Drops - Organic Lymphatic Support Liquid Drops Cleanse with Echinacea for Lymph System Support Supplement, Lymph Node Detox Cleanse System Drainage - 1oz Vegan Non-GMO
This listing is deemed profitablePrice (USD)$15.95Released TypeOld Release (2024-06-07)Brand is an old entry in this marketSize and Weight11.5 x 5.2 x 3.7 cm, 85.00gProfitable Factors
Based on old ASINDistinct functions and featuresDesign & Appearance
1盎司滴管液体瓶搭配黑色/蓝绿色草本包装，属于常见保健品滴剂设计Key Buying Motive
主打有机草本淋巴支持配方，强调液体滴剂形态、易吸收、可日常口服；相较竞品更突出 USDA Organic 与 Echinacea 复配Target Customers
面向偏好草本液体补充剂、希望用滴剂替代胶囊的人群，尤其是关注淋巴循环与免疫支持的保健型用户Early Investment
Investment
Monthly Revenue (Recent) (USD)$3,190.00200 sold in the past 30 days · as of 2026年7月Net Profit Margin
Sea Freight24.91% / 26.65%Peak / Non PeakRail Freight- / -Peak / Non PeakAir Freight22.31% / 24.05%Peak / Non PeakSales & BSR Performance
Loading samples... 67%